Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing facility at Pashamylaram, Hyderabad. The USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI).
Earlier, the USFDA had conducted an inspection of the aforesaid manufacturing facility from July 27, 2026, to August 5, 2026.
Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.